Once they reach their target weight, the weight comes back.
On the first day of 2026, California and three other states quietly withdrew Medicaid coverage for GLP-1 weight loss medications, leaving thousands of low-income patients without access to treatments that had, in many cases, transformed their lives. The decision reflects a familiar tension in public health policy: the gap between what medicine can do and what governments are willing to pay for. Even as federal negotiators drove the price of Wegovy down to a fraction of its former cost, state budget architects concluded the math still did not work — and in doing so, they made a different kind of calculation, one measured not in dollars but in the bodies of people who will now regain what they had lost.
- Thousands of low-income Californians lost coverage for GLP-1 weight loss drugs overnight on January 1st, with no transition plan and no warning beyond what was written into state budget law.
- California projected costs ballooning to $800 million annually within four years — a figure that overrode even a federal price negotiation that had cut Wegovy's monthly cost by nearly 75 percent.
- Medical experts are sounding alarms: obesity is a chronic condition, these drugs work precisely because they are taken indefinitely, and patients who stop them almost universally regain the weight.
- States that once appeared to be expanding GLP-1 coverage are now reversing course — Michigan, Rhode Island, and Wisconsin are considering similar cuts, signaling a broader retreat across Medicaid programs.
- Narrow lifelines exist — a cheaper pill form, out-of-pocket discounts, appeals hearings — but for most affected patients, the practical outcome is discontinued treatment and returning weight.
On January 1st, thousands of low-income Californians discovered their GLP-1 weight loss medications were no longer covered by Medi-Cal. Drugs like Wegovy and Zepbound, which had produced dramatic results for many patients, were suddenly off-limits for obesity treatment. Wilmer Cardenas of Santa Clara watched his husband lose nearly 100 pounds over two years on these medications — a transformation now in jeopardy.
California made this decision alongside New Hampshire, Pennsylvania, and South Carolina, even as the federal government had just negotiated Wegovy's price down from roughly $1,350 per month to $350 for consumers, with Medicaid paying $245. State officials projected that covering GLP-1s for weight loss would cost nearly $800 million annually within four years. When asked whether the new pricing would prompt reconsideration, a Department of Finance spokesperson said no — the decision was already written into law.
The move runs against a trend that had been building: as recently as October, sixteen states covered GLP-1s for obesity. That interest is now waning, according to the Kaiser Family Foundation, as budget pressures mount. North Carolina pulled coverage in October, only to reinstate it after a court order. Michigan, Rhode Island, and Wisconsin are weighing similar restrictions.
Health experts warn that California's pivot to recommending diet and exercise misunderstands how obesity treatment works. Kurt Hong of USC's Keck School of Medicine noted that patients who reach a doctor have typically already failed to achieve results through lifestyle changes alone. Diana Thiara of UCSF's Weight Management Program warned the cuts will be deeply harmful, since stopping these drugs almost always leads to weight regain. Obesity is a chronic condition — yet California's policy treats it as something that can be addressed and abandoned.
The state continues to cover GLP-1s for type 2 diabetes, cardiovascular disease, and kidney disease — just not for obesity itself. Children under 21 retain coverage under federal requirements, and adults who can demonstrate medical necessity for another condition may keep access. For everyone else, options are narrow: out-of-pocket costs, discount programs, or a newly approved pill form expected to cost around $149 per month. For thousands of patients, the practical reality is that treatment that was working will stop — and the weight will return.
On January 1st, thousands of low-income Californians woke to find their weight loss medications no longer covered by the state's Medicaid program. The drugs—Wegovy, Zepbound, and other GLP-1 medications that have become fixtures in American medicine cabinets—were suddenly off-limits for obesity treatment, even as patients and their doctors watched the results of years of treatment disappear into the past tense.
Wilmer Cardenas, who lives in Santa Clara, watched his husband lose roughly 100 pounds over two years on these medications. "Of course, he tried eating well and everything, but now with the medications, it's better—a 100% change," Cardenas said. That transformation is now at risk. California, along with New Hampshire, Pennsylvania, and South Carolina, made the same calculation on the same day: the drugs had become too expensive to cover for weight loss, even though the federal government had just negotiated their prices downward. The White House announced in November that Wegovy would drop from a list price of nearly $1,350 per month to $350 for consumers, with Medicaid paying $245. It was supposed to make coverage sustainable. States cut it anyway.
California's math was stark. State officials projected that covering GLP-1s for weight loss would cost nearly $800 million annually within four years—a figure that quadrupled what the state was already spending. The Trump administration's price cuts, they decided, would not change the equation enough. When asked if the state would reconsider in light of the negotiated reductions, a Department of Finance spokesperson said no. The decision was written into state budget law. California officials would not disclose how much they might save under the new pricing, citing restrictions on revealing rebate information.
The reversal is striking because it runs against momentum that had been building. As of October 1st, sixteen states covered GLP-1s for obesity. Interest in that coverage "appears to be waning," according to the most recent survey by the Kaiser Family Foundation, likely because of cost and other budget pressures. Michigan, Rhode Island, and Wisconsin are planning or considering similar restrictions. North Carolina pulled coverage in October but reinstated it in December after court orders forced the governor's hand, despite a lingering budget shortfall.
Health officials in California are now recommending diet and exercise as alternatives—advice that experts say misses the reality of how obesity treatment works. Kurt Hong, founding director of the Center for Clinical Nutrition at the Keck School of Medicine at USC, put it plainly: by the time patients reach a doctor, they have usually already failed at achieving results through diet and exercise alone. "We definitely want patients to do their part with the diet and exercise, but unfortunately, and from a practical standpoint, that in itself frequently is not enough," Hong said. These medications produce roughly twice the weight loss of older obesity drugs. They work. And when patients stop taking them, the weight typically returns.
Diana Thiara, medical director of the University of California-San Francisco Weight Management Program, warned that the coverage cuts "will be quite negative for our patients" because data shows people regain weight after stopping the drugs. Obesity is generally considered a chronic condition requiring indefinite treatment, not something to be cured and abandoned. Yet that is what California's policy assumes will happen. The state continues to cover GLP-1s for other conditions—type 2 diabetes, cardiovascular disease, chronic kidney disease—but not for the condition the drugs were designed to treat in these patients.
California's Medicaid program, known as Medi-Cal, has covered weight loss drugs since 2006, but the explosion in GLP-1 use is recent. By 2024, more than 645,000 prescriptions were covered across all uses. The state could not readily break down how many were for weight loss versus other conditions. Members under 21 will retain coverage for weight loss, citing a federal requirement. Adults can keep coverage if they can demonstrate medical necessity for another condition—which is where Cardenas's husband may find shelter, since his prescription is technically for diabetes, not weight loss.
For others, options exist but are narrow. Members can pay out of pocket and use various discounts. A pill version of Wegovy was approved by the FDA on December 22nd and is expected to cost $149 per month for the lowest dose—cheaper than injections, but still a barrier for those on Medicaid. Similar pills are expected in the first half of the year. Those denied coverage can request a hearing. But the practical reality is that thousands of people will stop taking medications that were working, and the weight they lost will come back. The White House did not respond to requests for comment on why states were terminating coverage despite the price negotiations.
Notable Quotes
Of course, he tried eating well and everything, but now with the medications, it's better—a 100% change.— Wilmer Cardenas, describing his husband's weight loss on GLP-1 medications
It will be quite negative for our patients because data shows people typically regain weight after stopping the drugs.— Diana Thiara, medical director of UCSF Weight Management Program
The Hearth Conversation Another angle on the story
Why would California reject the price cuts? The federal government negotiated them down significantly.
The cuts helped, but not enough. California's projection was that covering these drugs for weight loss would cost $800 million a year within four years. Even at the lower price, that's still a massive budget item for a state facing other pressures. The decision was written into law before the price negotiations were even announced.
So the timing was bad for patients.
Exactly. The state had already decided to cut coverage. When the White House announced lower prices, California didn't reconsider. Officials wouldn't even say how much they might save under the new plan.
What happens to people like Wilmer Cardenas's husband, who lost 100 pounds?
That's the hard part. The weight comes back. Medical experts are clear that obesity is a chronic condition. These drugs work—they produce twice the weight loss of older medications. But they require ongoing treatment. Once you stop, most people regain the weight.
Can't people just diet and exercise instead?
That's what California is officially recommending now. But doctors say that's unrealistic. By the time patients see them, they've usually already tried diet and exercise and failed. The state is essentially telling people to do something they've already proven they can't do.
Is California alone in this?
No. New Hampshire, Pennsylvania, and South Carolina did the same thing on January 1st. Michigan, Rhode Island, and Wisconsin are considering it. There was momentum toward coverage—sixteen states covered these drugs for obesity as of October. But interest is waning because of cost and budget pressure.
What's the way forward for patients who lose coverage?
Limited options. They can pay out of pocket. A pill version of Wegovy just got approved and will be cheaper than injections. But for people on Medicaid, that's still a barrier. Some might keep coverage if they can prove the drug is medically necessary for another condition, like diabetes. But for most, coverage is simply gone.